TScan Therapeutics directors Garry Nicholson and Gabriela Gruia resign; Woods and Biggar join NCG Committee
TScan Therapeutics announced board changes: Garry Nicholson and Gabriela Gruia resigned, while R. Keith Woods and Stephen Biggar joined the Nominating and Corporate Governance Committee. Woods became its chairperson. The changes were effective October 13, 2026, and were not due to disagreements with the company.
How this was made
The 30-second read
Why it matters
The filing provides the first public disclosure of these director changes, making it a primary source of corporate governance news.
Market read
Corporate governance update for a micro‑cap biotech; limited immediate trading impact but relevant for shareholders.
What to watch
Potential upcoming clinical trial updates or financing activities that could dominate price action.
Background
TScan Therapeutics (NASDAQ: TCRX) filed an 8‑K on Oct 16, 2026 announcing board changes.
Ticker impact
SEC 8‑K filing reports the resignation of two directors and the appointment of two new members to the Nominating and Corporate Governance Committee.
modest pressure as investors reassess board stability
Director resignations and new appointments are new, material corporate actions but involve a micro‑cap biotech, so the expected price move is limited.
Market effects
Minimal impact on the broader biotech sector; similar governance changes are routine.
U.S. market only; no regional ripple.
Low; limited to TScan Therapeutics shareholders.
Counterpoint
Board turnover could signal upcoming strategic shifts that may unlock value if new directors bring expertise.
Key entities
- personGarry Nicholson
Resigned director
- personGabriela Gruia, M.D.
Resigned director
- personR. Keith Woods
Appointed to Nominating and Corporate Governance Committee (Chairperson)
- personStephen Biggar
Appointed to Nominating and Corporate Governance Committee
